西地那非联合一氧化氮治疗新生儿先天性心脏病合并肺动脉高压的临床有效性研究  

Study on clinical efficacy of sildenafil combined with nitric oxide in the treatment of neonates with congenital heart disease and pulmonary hypertension

作　　者：胡俊彦 HU Jun-yan(Inner Mongolia Autonomous Region Maternal and Child Health Hospital,Hohhot 010010,China)

机构地区：[1]内蒙古自治区妇幼保健院,010010

出　　处：《中国现代药物应用》2025年第3期81-83,共3页Chinese Journal of Modern Drug Application

摘　　要：目的观察新生儿先天性心脏病合并肺动脉高压采用西地那非联合一氧化氮治疗的临床效果。方法100例先天性心脏病合并肺动脉高压患儿,以治疗模式的差异分为对照组和观察组,每组50例。对照组仅行一氧化氮常规治疗,观察组行西地那非联合一氧化氮治疗。对比两组超声心动图指标[右心室收缩末期内径(RVSD)]、血流动力学指标[肺动脉平均压(mPAP)、肺血管阻力(PVR)、经皮血氧饱和度(SpO_(2))]、临床疗效、不良反应发生率。结果治疗后,两组RVSD均小于本组治疗前,且观察组RVSD(2.71±0.41)cm小于对照组的(2.94±0.56)cm(P<0.05)。治疗后,两组mPAP、PVR低于本组治疗前,SpO_(2)高于本组治疗前,且观察组mPAP(47.42±5.18)mm Hg(1 mm Hg=50.133kPa)、PVR(857.54±104.27)(dyn·s)/cm低于对照组的(53.24±5.86)mmHg、(910.66±120.73)(dyn·s)/cm^(5),SpO_(2)(87.96±9.59)%高于对照组的(80.81±9.07)%(P<0.05)。观察组总有效率96.00%高于对照组的84.00%(P<0.05)。两组不良反应发生率对比差异无统计学意义(P>0.05)。结论对先天性心脏病合并肺动脉高压患儿在常规一氧化氮吸入治疗基础上联合西地那非用药,可有效改善患儿的超声心动图指标、血流动力学指标,提升临床疗效,且治疗安全性高,无严重不良反应,具有临床实践价值。Objective To observe the clinical effect of sildenafil combined with nitric oxide in the treatment of neonates with congenital heart disease and pulmonary hypertension.Methods 100 neonates with congenital heart disease and pulmonary hypertension were divided into control group and observation group based on differences in treatment modes,each with 50 patients.The control group was treated with conventional nitric oxide,and the observation group was treated with sildenafil combined with nitric oxide.Both groups were compared in terms of echocardiographic indexes[right ventricular systolic diameter(RVSD)],hemodynamic indexes[mean pulmonary artery pressure(mPAP),pulmonary vascular resistance(PVR),transcutaneous oxygen saturation(SpO_(2))],clinical efficacy and incidence of adverse reactions.Results After treatment,the RVSD in both groups was lower than that before treatment,and the observation group had lower RVSD of(2.71±0.41)cm than(2.94±0.56)cm in the control group(P<0.05).After treatment,mPAP and PVR in both groups were lower than those before treatment,while SpO_(2) was higher than that before treatment;the observation group had mPAP of(47.42±5.18)mm Hg(1 mm Hg=0.133 kPa)and PVR of(857.54±104.27)(dyn·s)/cm^(5),which were lower than(53.24±5.86)mm Hg and(910.66±120.73)(dyn·s)/cm5 in the control group;the observation group had higher SpO_(2) of(87.96±9.59)% than(80.81±9.07)% in the control group(P<0.05).The total effective rate of the observation group was 96.00%,which was higher than 84.00% of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For neonates with congenital heart disease and pulmonary hypertension,the combination of conventional nitric oxide treatment and sildenafil can effectively improve the echocardiogram and hemodynamic indicators of patients,enhance clinical efficacy,and have high treatment safety and no serious adverse reactions.It has clinical practical value.

关 键 词：西地那非 先天性心脏病 肺动脉高压 一氧化氮 临床有效性 

分 类 号：R722.1[医药卫生—儿科]